Arbutus Biopharma Corp (NASDAQ:ABUS) had its Outperform rating reiterated by Chardan Capital with a $11.00 price target

ME Staff
-
0

Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS)

Today, Chardan Capital reiterated its Buy rating on Arbutus Biopharma Corp (NASDAQ:ABUS) with a price target of $11.00.

There are 0 sell ratings, 3 hold ratings, 2 buy ratings, 0 strong buy ratings on the stock.

The current consensus rating on Arbutus Biopharma Corp (NASDAQ:ABUS) is Hold with a consensus target price of $8.80 per share, a potential 15.79% downside.

Some recent analyst ratings include

  • 7/16/2018-Chardan Capital Reiterated Rating of Buy.
  • 7/6/2018-B. Riley was Downgraded by analysts at B. Riley from a “Buy ” rating to a ” Neutral” rating. They now have a $9.00 price target on the stock, up previously from $9.00 .
  • 3/19/2018-Wedbush was Downgraded by analysts at Wedbush from a “Outperform ” rating to a ” Neutral” rating. They now have a $6.00 price target on the stock, up previously from $9.00 .
  • 11/7/2017-Leerink Swann Reiterated Rating of Market Perform.
  • 10/4/2017-JMP Securities Reiterated Rating of Outperform.
  • 6/2/2017-LADENBURG THALM/SH SH initiated coverage with a Buy rating.
  • 1/9/2017-Bloom Burton Upgrade from a “Accumulate ” rating to a ” Buy” rating.

Recent Insider Trading Activity For Arbutus Biopharma Corp (NASDAQ:ABUS)
Arbutus Biopharma Corp (NASDAQ:ABUS) has insider ownership of 7.60% and institutional ownership of 33.30%.

  • On 7/11/2018 Michael J Sofia, Insider, sold 10,000 with an average share price of $10.00 per share and the total transaction amounting to $100,000.00.
  • On 7/9/2018 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.91 per share and the total transaction amounting to $89,100.00.
  • On 7/5/2018 Michael J Sofia, Insider, sold 20,000 with an average share price of $8.20 per share and the total transaction amounting to $164,000.00.
  • On 7/3/2018 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.00 per share and the total transaction amounting to $80,000.00.
  • On 10/3/2017 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.00 per share and the total transaction amounting to $80,000.00.
  • On 8/15/2017 Michael J Sofia, Insider, sold 30,000 with an average share price of $3.70 per share and the total transaction amounting to $111,000.00.
  • On 8/24/2015 Richard C Henriques Jr, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00.

About Arbutus Biopharma Corp (NASDAQ:ABUS)
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Recent Trading Activity for Arbutus Biopharma Corp (NASDAQ:ABUS)
Shares of Arbutus Biopharma Corp closed the previous trading session at 10.42 −1.28 10.90% with 11.75 shares trading hands.